MEC-Cox: Machine-Learning-Assisted Generalized Entropy Calibration for ATT Marginal Hazard-Ratio Estimation
arXiv:2606.08305v1 Announce Type: cross Abstract: Externally controlled survival trials are increasingly used when concurrent randomized controls are infeasible, particularly in oncology and rare-disease settings with time-to-event endpoints. We target an average-treatment-effect-on-the-treated (ATT)-type marginal hazard-ratio estimand, comparing treatment with counterfactual control in the treated trial population, and estimate it using inverse-probability-weighted (IPW) Cox regression. Valid inference is challenging because IPW Cox regression depends on the weights through both event contrib
The increasing use of externally controlled survival trials, especially in oncology and rare diseases, necessitates robust statistical methods like MEC-Cox to improve the reliability of treatment effect estimation.
This development improves the accuracy of evaluating treatment efficacy in complex clinical trial settings, directly impacting drug development and regulatory approval, particularly for life-saving therapies.
The precision and validity of statistical inferences for marginal hazard-ratio estimation in trials without concurrent randomized controls are enhanced, reducing uncertainty in crucial medical decisions.
- · Pharmaceutical companies
- · Oncology researchers
- · Rare disease patients
- · Biostatisticians
More reliable evaluation of new treatments using real-world data or external controls increases the potential for faster drug development.
Improved confidence in clinical trial outcomes could expedite regulatory approvals for drugs in areas with unmet medical needs.
The broader adoption of sophisticated statistical methods might lead to a re-evaluation of ethical guidelines for clinical trial design, balancing traditional randomized control with advanced analytical techniques.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG